vs
NOVAVAX INC（NVAX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是NOVAVAX INC的1.0倍（$151.1M vs $147.3M），NOVAVAX INC同比增速更快（66.8% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-41.6M），过去两年NOVAVAX INC的营收复合增速更高（25.3% vs 5.1%）
诺瓦瓦克斯是一家总部位于美国马里兰州盖瑟斯堡的生物科技企业，专注于传染病疫苗研发。其开发的新冠疫苗现由赛诺菲负责商业化，同时还在布局流感、呼吸道合胞病毒（RSV）、禽流感、带状疱疹、艰难梭菌感染、疟疾等多个领域的疫苗管线。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
NVAX vs RGR — 直观对比
营收规模更大
RGR
是对方的1.0倍
$147.3M
营收增速更快
NVAX
高出63.2%
3.6%
自由现金流更多
RGR
多$53.9M
$-41.6M
两年增速更快
NVAX
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $147.3M | $151.1M |
| 净利润 | $17.5M | — |
| 毛利率 | 85.0% | 17.8% |
| 营业利润率 | 9.7% | 2.3% |
| 净利率 | 11.9% | — |
| 营收同比 | 66.8% | 3.6% |
| 净利润同比 | 121.6% | — |
| 每股收益（稀释后） | $0.28 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NVAXRGR
| Q4 25 | $147.3M | $151.1M | ||
| Q3 25 | $70.4M | $126.8M | ||
| Q2 25 | $239.2M | $132.5M | ||
| Q1 25 | $666.5M | $135.7M | ||
| Q4 24 | $88.3M | $145.8M | ||
| Q3 24 | $84.5M | $122.3M | ||
| Q2 24 | $415.5M | $130.8M | ||
| Q1 24 | $93.9M | $136.8M |
净利润NVAXRGR
| Q4 25 | $17.5M | — | ||
| Q3 25 | $-202.4M | $1.6M | ||
| Q2 25 | $106.5M | $-17.2M | ||
| Q1 25 | $518.6M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-121.3M | $4.7M | ||
| Q2 24 | $162.4M | $8.3M | ||
| Q1 24 | $-147.6M | $7.1M |
毛利率NVAXRGR
| Q4 25 | 85.0% | 17.8% | ||
| Q3 25 | 69.5% | 15.1% | ||
| Q2 25 | 93.6% | 3.9% | ||
| Q1 25 | 97.9% | 22.0% | ||
| Q4 24 | 58.5% | 22.8% | ||
| Q3 24 | 28.3% | 18.5% | ||
| Q2 24 | 88.9% | 22.3% | ||
| Q1 24 | 36.9% | 21.5% |
营业利润率NVAXRGR
| Q4 25 | 9.7% | 2.3% | ||
| Q3 25 | -252.7% | -2.7% | ||
| Q2 25 | 42.2% | -15.6% | ||
| Q1 25 | 77.4% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | -158.6% | 3.1% | ||
| Q2 24 | 38.7% | 6.9% | ||
| Q1 24 | -154.3% | 5.5% |
净利率NVAXRGR
| Q4 25 | 11.9% | — | ||
| Q3 25 | -287.3% | 1.2% | ||
| Q2 25 | 44.5% | -13.0% | ||
| Q1 25 | 77.8% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -143.5% | 3.9% | ||
| Q2 24 | 39.1% | 6.3% | ||
| Q1 24 | -157.2% | 5.2% |
每股收益（稀释后）NVAXRGR
| Q4 25 | $0.28 | $0.22 | ||
| Q3 25 | $-1.25 | $0.10 | ||
| Q2 25 | $0.62 | $-1.05 | ||
| Q1 25 | $2.93 | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | $-0.76 | $0.28 | ||
| Q2 24 | $0.99 | $0.47 | ||
| Q1 24 | $-1.05 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $735.1M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-127.8M | $283.8M |
| 总资产 | $1.2B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NVAXRGR
| Q4 25 | $735.1M | $92.5M | ||
| Q3 25 | $762.9M | $80.8M | ||
| Q2 25 | $612.3M | $101.4M | ||
| Q1 25 | $731.5M | $108.3M | ||
| Q4 24 | $923.1M | $105.5M | ||
| Q3 24 | $909.5M | $96.0M | ||
| Q2 24 | $1.0B | $105.6M | ||
| Q1 24 | $480.6M | $115.3M |
股东权益NVAXRGR
| Q4 25 | $-127.8M | $283.8M | ||
| Q3 25 | $-156.7M | $279.6M | ||
| Q2 25 | $37.6M | $289.3M | ||
| Q1 25 | $-75.6M | $321.5M | ||
| Q4 24 | $-623.8M | $319.6M | ||
| Q3 24 | $-526.4M | $314.9M | ||
| Q2 24 | $-431.7M | $321.5M | ||
| Q1 24 | $-867.1M | $332.0M |
总资产NVAXRGR
| Q4 25 | $1.2B | $342.0M | ||
| Q3 25 | $1.2B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.6B | $384.0M | ||
| Q3 24 | $1.7B | $373.5M | ||
| Q2 24 | $1.8B | $376.7M | ||
| Q1 24 | $1.4B | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-39.5M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-41.6M | $12.3M |
| 自由现金流率自由现金流/营收 | -28.2% | 8.2% |
| 资本支出强度资本支出/营收 | 1.4% | 2.1% |
| 现金转化率经营现金流/净利润 | -2.25× | — |
| 过去12个月自由现金流最近4个季度 | $-250.2M | $38.5M |
8季度趋势，按日历期对齐
经营现金流NVAXRGR
| Q4 25 | $-39.5M | $15.5M | ||
| Q3 25 | $107.8M | $12.9M | ||
| Q2 25 | $-127.5M | $14.7M | ||
| Q1 25 | $-185.5M | $11.1M | ||
| Q4 24 | $-87.3M | $20.0M | ||
| Q3 24 | $-144.8M | $9.4M | ||
| Q2 24 | $314.3M | $18.7M | ||
| Q1 24 | $-83.6M | $7.3M |
自由现金流NVAXRGR
| Q4 25 | $-41.6M | $12.3M | ||
| Q3 25 | $105.8M | $7.0M | ||
| Q2 25 | $-127.7M | $9.1M | ||
| Q1 25 | $-186.7M | $10.0M | ||
| Q4 24 | $-100.3M | $16.4M | ||
| Q3 24 | $-146.2M | $2.6M | ||
| Q2 24 | $311.4M | $10.1M | ||
| Q1 24 | $-90.4M | $5.6M |
自由现金流率NVAXRGR
| Q4 25 | -28.2% | 8.2% | ||
| Q3 25 | 150.2% | 5.5% | ||
| Q2 25 | -53.4% | 6.9% | ||
| Q1 25 | -28.0% | 7.4% | ||
| Q4 24 | -113.6% | 11.2% | ||
| Q3 24 | -173.0% | 2.1% | ||
| Q2 24 | 74.9% | 7.7% | ||
| Q1 24 | -96.4% | 4.1% |
资本支出强度NVAXRGR
| Q4 25 | 1.4% | 2.1% | ||
| Q3 25 | 2.9% | 4.6% | ||
| Q2 25 | 0.1% | 4.2% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 14.8% | 2.5% | ||
| Q3 24 | 1.6% | 5.5% | ||
| Q2 24 | 0.7% | 6.6% | ||
| Q1 24 | 7.3% | 1.3% |
现金转化率NVAXRGR
| Q4 25 | -2.25× | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | -1.20× | — | ||
| Q1 25 | -0.36× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 1.94× | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NVAX
| Licensing Royalties And Other | $107.9M | 73% |
| Products | $39.2M | 27% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
